Europe grants marketing approval of Truvada for use as PrEP
European Commission has given pharmaceutical company, Gilead, the green light to market Truvada as pre-exposure prophylaxis (PrEP) across the region
The European Commission has approved the antiretroviral drug, Truvada for use as pre-exposure prophylaxis (PrEP), to help reduce the risk of HIV transmission in HIV-negative people.
The pharmaceutical company who owns Truvada, Gilead, can now market the drug in all 28 countries of the European Union, subject to national regulations in each country.
Professor Jean-Michel Molina, MD, PhD, Hôpital Saint Louis in Paris and University of Paris stated that PrEP provides an additional HIV prevention tool for Europe: “In the past 30 years, we have seen significant progress in the way we treat HIV; however, infection rates have continued to rise. In 2014, we saw the highest number of newly diagnosed cases in the European Union ever recorded, with 94% of those with known cause transmitted through sexual contact.”
However, despite undisputed evidence that PrEP is an effective HIV prevention strategy, and particularly when used in combination with other HIV prevention methods, some countries are unwilling to step-up access to the drug by using public funds.
Both the UK and Australia have declined to subsidise the drug under their national health programmes.